Research and Markets: Allergan Inc.: PharmaVitae Profile - Analyze the impact of Allergan's acquisition of Esprit Pharma in 2007

Research and Markets(http://www.researchandmarkets.com/research/e83948/allergan_inc_pha) has announced the addition of the "Allergan Inc.: PharmaVitae Profile" company profile to their offering.

This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this title

- Benchmark Allergan's performance against key rivals in the prescription pharmaceutical sector

- Assess how the key Botox franchise stands up to the global recession and the arrival of further competitors

- Analyze the impact of Allergan's acquisition of Esprit Pharma in 2007, namely its movement into the urology therapy market

Key Topics Covered:

Chapter 1 About this profile

PharmaVitae Explorer database

Chapter structure

Executive summary

Quarterly news update

Company introduction

Company sales

Company financials

Key products and competitors

Data sourcing

Sales data

Analyst consensus

Chapter 2 Executive summary

Key findings

Prescription pharmaceutical sales and growth rate performance, 2002-14

Financial performance, 2002-14

Allergan: PharmaVitae forecasts at a glance

Strategic insight

Allergan is highly dependent upon sales of Botox

Botox plays a central role in Allergan's synergistic expansion

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Table of figures

Chapter 3 Quarterly news update

Product developments

Deals and alliances

Product deals

Technology deals

M&A activity

Company announcements

Future product milestones

Chapter 4 Company introduction

Key findings

Background

Key corporate developments

M&A history

Acquired by SmithKline Beckman

Allergan spun-out from SmithKline Beckman

Acquisition of Oculinum

Divestment of Allergan Humphrey

Divestment of contact lens businesses

Five acquisitions were made in and around 1995

Allergan Specialty Therapeutics spun-out

Allergan Specialty Therapeutics re-acquired

Bardeen Sciences set-up

Advanced Medical Optics spun-out

Bardeen Sciences acquired

Oculex acquired

Acquistition of Inamed

Groupe Corneal Laboratoires acquired

EndoArt acquired

Acquisition of Esprit Pharma

Current corporate structure

Pharmaceuticals

Allergan Medical

Chapter 5 Company sales

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2002-14

Product analysis

Product analysis, 2002-08

Product analysis, 2008-14

Therapy area analysis

Geographic analysis

Launch/core/expiry analysis

Explanation of launch/core/expiry analysis

Launch analysis, 2008-14

Core analysis, 2008-14

Expiry analysis, 2008-14

Launch/core/expiry configuration, 2008-14

Molecule type analysis

Externalization analysis

Chapter 6 Company financials

Key findings

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08

Operating costs and profit analysis

Operating costs and profit analysis, 2002-08

Operating cost ratio and profit margin analysis, 2002-08

Operating cost ratio and profit margin analysis, 2008-14

Operating costs and profit analysis, 2008-14

Chapter 7 Key products and competitors

Key findings

Overview

Central nervous system

Botox

Overview

Sales forecast

Other (ophthalmology)

Restasis

Overview

Sales forecast

Lumigan franchise

Overview

Sales forecast

Alphagan franchise

Overview

Sales forecast

Ozurdex

Overview

Sales forecast

Ozurdex offers significant benefits over the standard of care

Other (skin care)

Latisse

Overview

Sales forecast

Chapter 8 Appendix

R&D pipeline

Reconciliation with reported figures

References

Abbreviations

Exchange rates

About Datamonitor

About Datamonitor Healthcare

Datamonitor consulting

Disclaimer

List of Tables

Companies Mentioned:

Advanced Medical Optics Inc

Advanced Micro Devices, Inc.

Eagle Bulk Shipping

Elan Corporation, plc

Esprit Holdings Limited

Galderma S.A.

GlaxoSmithKline Plc

IMS Health

Inspire Pharmaceuticals, Inc

Ipsen

ISTA Pharmaceuticals, Inc.

Kyorin Pharmaceutical Co. Ltd.

Mentor Corp.

Merck & Co., Inc.

Merck KGaA

Merz GmbH & Co.

Novartis AG

Novo Nordisk A/S

NPS Pharmaceuticals Inc

Nycomed

Pfizer Inc

Servier

The Depository Trust & Clearing Corporation

For more information visit http://www.researchandmarkets.com/research/e83948/allergan_inc_pha

Source: Datamonitor

CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (from USA) Fax: +353 1 481 1716 (rest of the world) e-mail: press@researchandmarkets.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, consulting, corporate, drugs, e-mail, executive, expansion, forecasts, health, healthcare, investment opinion, market, medical, optics, pharmaceuticals, pipeline, products, profit, recession, sales, shipping, technology, web